3rd Jun 2005 15:40
3 June 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that on 2 June 2005 Mr Robin Buchanan, a non-executivedirector of the Company, acquired 2,500 American depositary receipts,representing 7,500 ordinary shares of ‚£0.05 each in the Company, at a price of$31.72 per American depositary receipt. The Company was notified on 2 June2005.As a result of this transaction, Mr Buchanan has a total interest in 7,500ordinary shares of ‚£0.05 each in the Company.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com.Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire